Encouragingly, similar local immune potentiation of the primary melanoma excision site and the sentinel lymph node with the Toll-like receptor-9 ligand CpG-B in two randomized phase II trials of early-stage patients with melanoma led to activation of dendritic cell subsets. Here, TLR9 is linked to melanoma.